Profiles

Keywords
Last Name
Institution

Donald M. Jensen

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Digestive Diseases and Nutrition
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 7402549621.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Jensen DM, Rzepczynski A, Jensen EE, Reau N. The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents. Hepatology. 2022 Apr 13. PMID: 35416324.
      View in: PubMed
    2. Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther. 2019; 13:2565-2577. PMID: 31534310.
      View in: PubMed
    3. Mikolajczyk AE, Farnan JM, McConville JF, Jensen DM, Reddy KG, Te HS, Reau N, Aronsohn AI. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology. 2016 12; 64(6):2210-2218. PMID: 27506929.
      View in: PubMed
    4. Jensen DM, Sebhatu P, Reau NS. Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8. PMID: 27306302.
      View in: PubMed
    5. Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. Ann Hepatol. 2016 May-Jun; 15(3):333-49. PMID: 27049487.
      View in: PubMed
    6. Kataria Y, Deaton RJ, Enk E, Jin M, Petrauskaite M, Dong L, Goldenberg JR, Cotler SJ, Jensen DM, van Breemen RB, Gann PH. Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer. BMC Gastroenterol. 2016 Feb 29; 16:30. PMID: 26927700.
      View in: PubMed
    7. Kao JH, Jensen DM, Manns MP, Jacobson I, Kumada H, Toyota J, Heo J, Yoffe B, Sievert W, Bessone F, Peng CY, Roberts SK, Lee YJ, Bhore R, Mendez P, Hughes E, Noviello S. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int. 2016 07; 36(7):954-62. PMID: 26683763.
      View in: PubMed
    8. Jensen DM, Brunda M, Elston R, Gane EJ, George J, Glavini K, Hammond JM, Le Pogam S, Nájera I, Passe S, Piekarska A, Rodriguez I, Zeuzem S, Chu T. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016 Apr; 36(4):505-14. PMID: 26519669.
      View in: PubMed
    9. Mikolajczyk AE, Aronsohn AA, McConville JF, Jensen DM, Farnan JM. A call to action: The need for hepatology-focused educational interventions in Internal Medicine Residency training. Hepatology. 2015 Aug; 62(2):655-6. PMID: 25363161.
      View in: PubMed
    10. Welch NM, Jensen DM. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int. 2015 Jan; 35 Suppl 1:11-7. PMID: 25529082.
      View in: PubMed
    11. Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H, Vierling JM, Yoshida EM, Perez-Gomez HR, Scalori A, Hooper GJ, Tavel JA, Navarro MT, Shahdad S, Kulkarni R, Le Pogam S, Nájera I, Eng S, Lim CY, Shulman NS, Yetzer ES. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302. PMID: 25239078.
      View in: PubMed
    12. Petty LA, Steinbeck JL, Pursell K, Jensen DM. Human immunodeficiency virus and coinfection with hepatitis B and C. Infect Dis Clin North Am. 2014 Sep; 28(3):477-99. PMID: 25151567.
      View in: PubMed
    13. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1604-14. PMID: 24720679.
      View in: PubMed
    14. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9. PMID: 24493069.
      View in: PubMed
    15. Jensen DM, Nathanson MH. Faster than a speeding bullet. Hepatology. 2014 Mar; 59(3):741-2. PMID: 24497126.
      View in: PubMed
    16. Marcellin P, Craxi A, Brandao-Mello CE, Di Bisceglie AM, Andreone P, Freilich B, Rajender Reddy K, Olveira Martín A, Teuber G, Messinger D, Hooper G, Wat C, Tatsch F, Jensen DM. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment. J Clin Gastroenterol. 2013 Oct; 47(9):786-93. PMID: 23442834.
      View in: PubMed
    17. Fried MW, Jensen DM. The FDA, bridging data, and hepatitis C. Hepatology. 2013 Mar; 57(3):875-7. PMID: 23456679.
      View in: PubMed
    18. Dabbouseh NM, Jensen DM. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013 May; 10(5):268-76. PMID: 23419289.
      View in: PubMed
    19. Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012 Dec; 56(6):2398-403. PMID: 22707382.
      View in: PubMed
    20. Jenkins ET, Jensen DM. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus. Infect Dis Clin North Am. 2012 Dec; 26(4):879-91. PMID: 23083821.
      View in: PubMed
    21. Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D. Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat. 2012; 2012:138302. PMID: 23094146.
      View in: PubMed
    22. Marcellin P, Roberts SK, Reddy KR, Harrison SA, Jensen DM, Hadziyannis S, Diago M, Weltman M, Messinger D, Tatsch F, Rizzetto M. Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf. 2012 Nov; 11(6):901-9. PMID: 22943161.
      View in: PubMed
    23. Te HS, Dasgupta KA, Cao D, Satoskar R, Mohanty SR, Reau N, Millis JM, Jensen DM. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32. PMID: 22554357.
      View in: PubMed
    24. Jensen DM, Pol S. IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? Liver Int. 2012 Feb; 32 Suppl 1:74-8. PMID: 22212576.
      View in: PubMed
    25. Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM, Marcellin P, Pockros PJ, Rodríguez-Torres M, Rossaro L, Rustgi VK, Sepe T, Sulkowski M, Thomason IR, Yoshida EM, Chan A, Hill G. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol. 2012 Jan-Feb; 11(1):15-31. PMID: 22166557.
      View in: PubMed
    26. Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, Jensen DM, Mangia A, Buti M, Sheppard F, Ferenci P, Thévenot T. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology. 2011 Sep 02; 54(3):789-800. PMID: 21674553.
      View in: PubMed
    27. Jensen DM. A new era of hepatitis C therapy begins. N Engl J Med. 2011 Mar 31; 364(13):1272-4. PMID: 21449791.
      View in: PubMed
    28. Jensen DM. Treatment duration for genotypes 2 and 3: still confusing after all these years. J Clin Gastroenterol. 2010 Sep; 44(8):527-8. PMID: 20628314.
      View in: PubMed
    29. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010 Feb; 14(1):1-21, vii. PMID: 20123436.
      View in: PubMed
    30. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009 Apr 21; 150(8):528-40. PMID: 19380853.
      View in: PubMed
    31. McGreal N, Jensen DM. Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. Liver Int. 2009 Apr; 29(4):481-2. PMID: 19323778.
      View in: PubMed
    32. Jensen DM. Individualizing HCV Treatment with Peginterferon and Ribavirin: What needs to be Done? Therap Adv Gastroenterol. 2009 Jan; 2(1):5-10. PMID: 21180530.
      View in: PubMed
    33. Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol. 2009 Apr; 50(4):797-804. PMID: 19231016.
      View in: PubMed
    34. Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR, Pockros PJ, Lin A, Cupelli L, Duff F, Wang K, Nelson DR. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. 2008 Oct; 48(4):1033-43. PMID: 18697207.
      View in: PubMed
    35. Mishra P, DeVoss A, Pai R, Hart J, Jensen DM. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report. Dig Dis Sci. 2009 Jun; 54(6):1369-72. PMID: 18770036.
      View in: PubMed
    36. Mishra P, Jensen DM. Hepatitis C: current and future therapies. Mt Sinai J Med. 2008 Aug; 75(4):405-14. PMID: 18729159.
      View in: PubMed
    37. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8. PMID: 18796095.
      View in: PubMed
    38. Te HS, Anderson AS, Millis JM, Jeevanandam V, Jensen DM. Current state of combined heart-liver transplantation in the United States. J Heart Lung Transplant. 2008 Jul; 27(7):753-9. PMID: 18582805.
      View in: PubMed
    39. Martin P, Jensen DM. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 2008 Jun; 23(6):844-55. PMID: 18565019.
      View in: PubMed
    40. Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis. 2008 Feb; 12(1):203-17, x. PMID: 18242505.
      View in: PubMed
    41. Jensen DM, Ascione A. Future directions in therapy for chronic hepatitis C. Antivir Ther. 2008; 13 Suppl 1:31-6. PMID: 18432161.
      View in: PubMed
    42. Satoskar R, Jensen DM. Retreatment of chronic hepatitis C in previous non-responders and relapsers. Expert Opin Pharmacother. 2007 Oct; 8(15):2491-503. PMID: 17931085.
      View in: PubMed
    43. Sauk J, Jensen DM, Mohanty SR, Reau N, Reddy KG, Te HS. Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis. Gastroenterol Hepatol (N Y). 2006 Jul; 2(7):504-508. PMID: 28289353.
      View in: PubMed
    44. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006 May; 43(5):954-60. PMID: 16628671.
      View in: PubMed
    45. Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol. 2005 Sep; 17(9):899-904. PMID: 16093865.
      View in: PubMed
    46. Cohen SM, Gundlapalli S, Shah AR, Johnson TJ, Rechner JA, Jensen DM. The downstream financial effect of hepatology. Hepatology. 2005 May; 41(5):968-75. PMID: 15841443.
      View in: PubMed
    47. Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol. 2004 Oct; 38(9):801-4. PMID: 15365409.
      View in: PubMed
    48. Sotil EU, Jensen DM. Serum enzymes associated with cholestasis. Clin Liver Dis. 2004 Feb; 8(1):41-54, vi. PMID: 15062192.
      View in: PubMed
    49. Kaplan M, Gawrieh S, Cotler SJ, Jensen DM. Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. Gastroenterology. 2003 Aug; 125(2):597-604. PMID: 12891562.
      View in: PubMed
    50. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman SV, Fried MW, Rasenack J, Sarrazin C, Jensen DM, Lin A, Hoffman JH, Sedarati F. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol. 2003 Jul; 39(1):106-11. PMID: 12821051.
      View in: PubMed
    51. Cotler SJ, Cotler S, Gambera M, Benedetti E, Jensen DM, Testa G. Adult living donor liver transplantation: perspectives from 100 liver transplant surgeons. Liver Transpl. 2003 Jun; 9(6):637-44. PMID: 12783411.
      View in: PubMed
    52. Cotler SJ, Morrissey MJ, Wiley TE, Layden TJ, Jensen DM. A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. J Clin Gastroenterol. 2003 Apr; 36(4):352-5. PMID: 12642744.
      View in: PubMed
    53. Cotler SJ, Diaz G, Gundlapalli S, Jakate S, Chawla A, Mital D, Jensik S, Jensen DM. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol. 2002 Aug; 35(2):191-5. PMID: 12172367.
      View in: PubMed
    54. Cotler SJ, Craft T, Ferris M, Morrisey M, McCone J, Reddy KR, Conrad A, Jensen DM, Albrecht J, Taylor MW. Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1. J Interferon Cytokine Res. 2002 May; 22(5):549-54. PMID: 12060493.
      View in: PubMed
    Jensen's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (229) concept(s)
    _
    Co-Authors Expand Description
    See all (4) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department